Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15099
|
| Title: | Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes |
| Authors: | Yen, FS;Hou, MC;CC Wei, J;Shih, YH;Hsu, CY;Hsu, CC;Hwu, CM |
| Contributors: | Institute of Population Health Sciences;National Center for Geriatrics and Welfare Research |
| Abstract: | BACKGROUND & AIMS: Liver cirrhosis is often associated with type 2 diabetes (T2D), but research on treatment of T2D in cirrhotic patients is scarce. We investigated the long-term outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with T2D and cirrhosis. METHODS: Using propensity-score matching, we selected 467 matched pairs of GLP-1 RA users and nonusers from the National Health Insurance Research Database of Taiwan from January 1, 2008, to December 31, 2019. Multivariable-adjusted Cox proportional hazards models were used to compare the outcomes between GLP-1 RA users and nonusers. RESULTS: The mean follow-up time was 3.28 and 3.06 years for GLP-1 RA users and nonusers, respectively. The rates of death were 27.46 and 55.90 per 1000 person-years for GLP-1 RA users and nonusers, respectively. The multivariable-adjusted models showed that GLP-1 RA users had lower risks of mortality (aHR 0.47, 95%CI 0.32-0.69), cardiovascular events (aHR 0.6, 95%CI 0.41-0.87), decompensated cirrhosis (aHR 0.7, 95%CI 0.49-0.99), hepatic encephalopathy (aHR 0.59, 95%CI 0.36-0.97), and liver failure (aHR 0.54, 95%CI 0.34-0.85) than nonusers. A longer cumulative duration of GLP-1 RA use had a lower risk of these outcomes than GLP-1 RA no-use. CONCLUSIONS: This population-based cohort study showed that GLP-1 RA users exhibited a significantly lower risk of death, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver failure in patients with T2D and compensated liver cirrhosis. Additional studies are needed to confirm our results. |
| Date: | 2024-06 |
| Relation: | Clinical Gastroenterology and Hepatology. 2024 Jun;22(6):1255-1264.e18. |
| Link to: | http://dx.doi.org/10.1016/j.cgh.2023.06.004 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1542-3565&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001246279400001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85165633010 |
| Appears in Collections: | [許志成] 期刊論文
[許志成] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB37331413.pdf | | 1771Kb | Adobe PDF | 134 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
